Art. -Nr.: HY-134901

WM-3835

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.78%
CAS. Nr.: 2229025-70-9
Formel: C₂₀H₁₇FN₂O₄S
Molecular Weight:400.42

Speicherung:

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

WM-3835 Chemical Structure

CAS. Nr.: 2229025-70-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

HBO1

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen :

In Vitro

WM-3835 (1-25 uM; 24-96 hours) inhibits pOS-1 cell viability in a concentration-dependent manner^[1].
WM-3835 (5 uM; 72 h) activates cell apoptosis and significantly increases TUNEL-positive nuclei in pOS-1 cells^[1].
WM-3835 (5 μM; 24 hours) downregulates MYLK-HOXA9 mRNA expression in pOS-1 cells^[1].
WM-3835 (1-25 uM) suppresses H4K12ac-H3K14ac in a dose-dependent manner. WM-3835 does not alter the expressions of HBO1 protein and total H3, H4 histones^[1].
WM-3835 (5 μM) fails to induce apoptosis and reduction of viability in HBO1-KO pOS-1 cells, koHBO1-1 and koHBO1-2, HBO1-low human osteoblasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Primary human OS (pOS-1) cells
Concentration:

1, 5, 10, 25 uM
Incubation Time:

24, 48, 72, 96 hours
Result:

Inhibited pOS-1 cell viability in a concentration-dependent manner.
Exerted a significant anti-survival activity at least 48 h, displaying a time-dependent manner.

Apoptosis Analysis^[1]

Cell Line:

pOS-1 cells
Concentration:

5 uM
Incubation Time:

72 hours
Result:

Activated cell apoptosis and significantly increases TUNEL-positive nuclei.

RT-PCR^[1]

Cell Line:

pOS-1 cells
Concentration:

5 uM
Incubation Time:

24 hours
Result:

Downregulated MYLK-HOXA9 mRNA expression.

In Vivo

WM-3835 (10 mg/kg/day; ip; for21 days) potently inhibits pOS-1 xenograft growth in SCID mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SCID mice (18-19 g, female) with pOS1 cells^[1]
Dosage:

10 mg/kg
Administration:

IP; daily; for 21 days
Result:

Potently inhibited pOS-1 xenograft growth.

Chemical Information

CAS. Nr. 2229025-70-9
Appearance Solid
Molecular Weight 400.42
Formel C₂₀H₁₇FN₂O₄S
Color White to off-white
SMILES

O=C(C1=CC(C2=CC=CC=C2)=CC(C)=C1F)NNS(=O)(C3=CC=CC(O)=C3)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Publications (11)

All Cell Proliferation/Viability AssayWBFlow CytometryRT-PCR

Sort by:

Journal Impact Factor

Nat Cell Biol

An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs. [Abstract]

2026 Mar 27. PMID: 41896311
Sci Adv

DOT1L is a barrier to histone acetylation during reprogramming to pluripotency. [Abstract]

2023 Nov 15;9(46):eadf3980. PMID: 37976354
Blood Cancer Discov

2026 Apr 19.
Cell Death Dis

Histone acetylation by HBO1 (KAT7) activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia. [Abstract]

2023 Aug 4;14(8):498. PMID: 37542030

WM-3835 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Aug 4;14(8):498. [Abstract]

Dose-effect curves of the inhibitory action of WM-3835 (0.1-100 μM) on listed cells in vitro for 96 h.The results showed that WM-3835 significantly inhibited the viability of B-ALL cell lines and primary cells derived from B-ALL patients in a concentration-dependent manner (Fig. A, B), but had no effect on the viability of normal human peripheral blood mononuclear cells (PBMCs) and HBO1 knockdown B-ALL cells (Fig. C, D).

WM-3835 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Aug 4;14(8):498. [Abstract]

Cell cycle progression was detected by FACS (left) and statistically analyzed (right) after NALM-6 and REH cells were treated with 0.1% DMSO or 2 μM WM-3835 for 96 hours.
Dev Cell

Dual function of PHF16 in reinstating homeostasis of murine intestinal epithelium after crypt regeneration. [Abstract]

2024 Aug 27:S1534-5807(24)00492-1. PMID: 39232563
Cell Rep

SPT6 regulates H3K14Ac deposition in mouse embryonic stem cells. [Abstract]

2025 May 30;44(6):115757. PMID: 40450685

WM-3835 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 May 30;44(6):115757. [Abstract]

Western blots showing H3K14Ac levels in mES cells treated with KAT7 inhibitor (WM-3835, 10-100 μM; 3-12 h) for gradient duration and concentration.
J Hypertens

KAT7 contributes to ponatinib-induced hypertension by promoting endothelial senescence and inflammatory responses through activating NF-κB signaling pathway. [Abstract]

2025 May 1;43(5):827-840. PMID: 40084466

WM-3835 purchased from MedChemExpress. Usage Cited in: J Hypertens. 2025 May 1;43(5):827-840. [Abstract]

Cell viability was measured by CCK-8 in MAECs under control condition or treated with 100 nM ponatinib in the absence or in the presence of 100 nM WM-3835 for 24 h. The data are means ± SEM, n = 7 per group. ∗P < 0.05 versus control; #P < 0.05 versus ponatinib.

WM-3835 purchased from MedChemExpress. Usage Cited in: J Hypertens. 2025 May 1;43(5):827-840. [Abstract]

Western blot analysis (upper) and summarized data (lower) of p21 expression in MAECs under control condition or treated with 100 nM Ponatinib in the absence or in the presence of 100 nM WM-3835 for 24 h. The data are means ± SEM, n = 6 per group. ∗P < 0.05 versus control; #P < 0.05 versus ponatinib.

WM-3835 purchased from MedChemExpress. Usage Cited in: J Hypertens. 2025 May 1;43(5):827-840. [Abstract]

IL-6 and IL-8 levels were measured in MAECs under control condition or treated with 100 nM Ponatinib in the absence or in the presence of 100 nM WM-3835 for 24 h by PCR. The data are means ± SEM, n = 6 per group. ∗P < 0.05 versus control; #P < 0.05 versus ponatinib.
bioRxiv

MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemia. [Abstract]

2026 Jan 8:2026.01.08.697228. PMID: 41542431
University of Wisconsin

2025.
Res Sq

An EGFR Co-Amplified and De Novo Long Noncoding RNA HELDR Promotes Glioblastoma Malignancy through KAT7-Driven Gene Programs. [Abstract]

2025 Jun 24:rs.3.rs-6456987. PMID: 40678238
bioRxiv

A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer. [Abstract]

2025 Apr 26:2025.04.23.650241. PMID: 40568091

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 175 mg/mL (437.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4974 mL

12.4869 mL

24.9738 mL

5 mM

0.4995 mL

2.4974 mL

4.9948 mL

10 mM

0.2497 mL

1.2487 mL

2.4974 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yan-Yang Gao, et al. The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma. Theranostics. 2021 Mar 4;11(10):4599-4615. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4974 mL	12.4869 mL	24.9738 mL	62.4344 mL
	5 mM	0.4995 mL	2.4974 mL	4.9948 mL	12.4869 mL
	10 mM	0.2497 mL	1.2487 mL	2.4974 mL	6.2434 mL
	15 mM	0.1665 mL	0.8325 mL	1.6649 mL	4.1623 mL
	20 mM	0.1249 mL	0.6243 mL	1.2487 mL	3.1217 mL
	25 mM	0.0999 mL	0.4995 mL	0.9990 mL	2.4974 mL
	30 mM	0.0832 mL	0.4162 mL	0.8325 mL	2.0811 mL
	40 mM	0.0624 mL	0.3122 mL	0.6243 mL	1.5609 mL
	50 mM	0.0499 mL	0.2497 mL	0.4995 mL	1.2487 mL
	60 mM	0.0416 mL	0.2081 mL	0.4162 mL	1.0406 mL
	80 mM	0.0312 mL	0.1561 mL	0.3122 mL	0.7804 mL
	100 mM	0.0250 mL	0.1249 mL	0.2497 mL	0.6243 mL

WM-3835

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

WM-3835

Apoptosis Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) WM-3835

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WM-3835

Apoptosis Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) WM-3835

Alle Histone Acetyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WM-3835 Related Classifications

HY-134901 Related Classifications